Chicago, Illinois – The 10th Annual Oncology Innovation Forum (#Sachs_OIF) will take place at the Waldorf Astoria Chicago Hotel on the 31st of May 2024, at the beginning of the ASCO meeting. The Virtual Week will follow from the 12th to 14th of June.
The 10th Annual OIF is an established networking opportunity for senior biotech executives to meet Pharma Licensing teams and financial and corporate investors and their advisers. Meetings take place alongside a stimulating program focusing on the latest trends in pharma-biotech dealmaking, the latest innovation in IO targets and modalities. There is also an ASCO forecast panel with industry analysts sharing their views on what to expect. This will be available on demand for the virtual audience the week after ASCO. Additionally, there will be pre-arranged in-person and virtual meetings, live and on-demand company showcases, and a reception.
The event brings together leaders from cancer research institutes, patient advocacy groups, pharma, biotech, and Wall Street, to facilitate partnering, funding and investment. We anticipate around 250 delegates and 20+ company presentations by established and emerging companies with part of the audience participating virtually. This will include a limited number of live presentations taking place in dedicated presentation tracks, alongside virtual company showcases, which will be available on demand. Recorded sessions will also be added on demand on the events portal during the virtual week.
The programme will consist of:
Friday, 31st of May (Central Daylight Time (CDT) zone):
BioPharma Dealmakers Roundtable
New Endpoints for Early-Stage Oncology Companies Panel
Investing in NextGen ADCs Panel
Advanced Immunotherapies Panel: Cell Therapies & Cancer Vaccines
New Methods of Therapeutic Delivery for Oncology Panel
New Hubs for Innovation Panel
ASCO Forecast Discussion
Networking Reception – 31st of May
In-Person Meetings – 31st of May
Virtual Meetings via Online Meeting System – 12th – 14th of June (Eastern Standard Time (EST) zone)
Confirmed Speakers & Chairs Include:
Andreas Pahl, CEO, Heidelberg Pharma AG
Benjamin Burnett, Equity Research, Stifel
Brad Loncar, Founder, BiotechTV
Chris Sheldon, SVP, Head of Business Development, GSK
Colette Lipp, Director, Global BD Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany
David G. Benathan, VP, BD&L Partnering Head Oncology, Novartis Pharma AG
Deborah Rathjen, Managing Director & CEO, Carina Biotech
Devang Bhuva, SVP, Corporate Development, Gilead Sciences, Inc.
Evonne Sepsis, Managing Director, ESC Advisors
Gregor Fachinger, Head BD Oncology, Merck KGaA, Darmstadt, Germany
Jacob Plieth, Senior Journalist, ApexOnco
James Barlow, President & CEO, ImmunoGenesis Inc.
Jay Olson, Managing Director & Senior Analyst, Oppenheimer & Co. Inc.
Jean-Pierre Latere, CEO, EsoBiotec
Jeffrey Bockman, EVP, BioConsulting, Head of Oncology, Lumanity
Joel Sandler, Associate Partner, Ipsos Healthcare Advisory Service
John DeYoung, VP, Worldwide Business Development, Pfizer, Inc.
Jun Xu, Executive Director of the Therapy Acceleration Program, The Leukemia & Lymphoma Society
Kaveri Pohlman, Director, Biotechnology Equity Research, BTIG, LLC
Matthew Price, Co-Founder, EVP & Chief Operating Officer, Promontory Therapeutics Inc.
Michael Kingston, Managing Director & Head of North America Life Sciences, Lazard Ltd.
Michael Rice, Expert Advisor, SVP, Cell & Gene Therapy, Lumanity
Michael Salgaller, Supervisor, Technology Analysis & Marketing Unit (TAMU), National Institutes of Health (NIH)
Michal Preminger, Regional Head, Johnson & Johnson Innovation East North America, Johnson & Johnson Innovation LLC
Nadim Ahmed, President & CEO, Cullinan Oncology, Inc
Niels Emmerich, VP, Search & Evaluation & Global Alliances, AbbVie, Inc.
Niranjan Sardesai, Founder, President & CEO, Geneos Therapeutics, Inc.
Omari Wise, VP Transactions, Amgen, Inc.
Paul Rennert, CEO, Aleta Biotherapeutics
Pete DeMuth, CSO, Elicio Therapeutics, Inc.
Peter Sandor, SVP, PFL Oncology, Astellas Pharma, Inc.
Raven Lin, Co-Founder & Interim CEO, Pilatus Biosciences SA
Sam Fazeli, Head of Research, Senior Pharmaceuticals Analyst, Bloomberg Intelligence
Sath Nirmalananthan, CFO, Scancell
Sharon Chan, VP JLABS Asia Pacific, Johnson & Johnson Innovation LLC
Uciane Scarlett, Principal Venture Capitalist, MPM BioImpact
Vivek Abraham, Director, Oncology Search & Evaluation, AbbVie, Inc.
Xavier Avat, CBO & EVP, Moffitt Cancer Center Foundation
Yuval Cohen, CEO, Corbus Pharmaceuticals Holdings, Inc.
More TBA…
PARTICIPATION OPTIONS INCLUDE
Complimentary passes are provided for qualified institutional (buy/sell-side), private equity and venture investors. The number of passes is limited, and priority is given to regular participants, however the organiser has the discretion to reject registrations. Other participants may consider purchasing access, which includes in-person or virtual participation, with different options to showcase your company.
NETWORKING OPPORTUNITIES
The Online Meeting System will open on the 17th of May for uploading profiles and sending meeting invites. The in-person meetings will be taking place on the 31st of May, while virtual meetings will take place on the 12th – 14th of June. For the virtual meetings, the system will allow you to have a secure audio/video call, as well as an option to present slides using a screen share function and we will have a dedicated room for in-person meetings.
PRESENTING OPPORTUNITIES
Gain additional exposure to high-level decision makers by presenting at the forum, which offers excellent opportunities to showcase your company’s investment and partnering offering. This typically includes technology and financial highlights. This adds to the news flow from the forum and generates greater interest in meetings from other delegates.
Presentations are a popular and useful way to gain additional exposure with potential investors and pharma partners, which make up over half the audience. We are pleased to announce that once again we will have 20-minute and 10-minute presentations taking place in-person at the dedicated presenting tracks. Here you will be able to showcase your company in front of investors attending the physical event. The recording will be added to your company’s profile during the virtual week, which will be available on demand for registered participants until the event portal closes.
For those who cannot present in-person, but are still interested to showcase their company, there is an option to purchase either a 20 or 10 minute presentation, which will be pre-recorded in advance and available to all registered attendees on the events portal. Start-up companies may also purchase a 5-minute pre-recorded showcase instead.
The Sachs Team can assist with the pre-recording of the presentation, or you can upload a video you already have. Interested viewers will be able to message or request a meeting with you using the Online Meeting System.
For further details about the forum, including registration, please click here.
Forum at a glance
When: May 31st, 2024
Venue: Waldorf Astoria Chicago Hotel – 11 E Walton St, Chicago, IL 60611, USA